Jasper Therapeutics Inc
JSPR2.905USD
+0.025+0.87%
Market hours （ET）Quotes delayed by 15 min
43.64MMarket Cap
LossP/E TTM
More Details of Jasper Therapeutics Inc Company
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
Company Info
Ticker SymbolJSPR
Company nameJasper Therapeutics Inc
IPO dateNov 20, 2019
CEOMr. Ronald A. (Ron) Martell
Number of employees64
Security typeOrdinary Share
Fiscal year-endNov 20
Address2200 Bridge Pkwy Suite #102
CityREDWOOD CITY
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94065
Phone16505491400
Websitehttps://jaspertx.com/
Ticker SymbolJSPR
IPO dateNov 20, 2019
CEOMr. Ronald A. (Ron) Martell
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Ronald A. (Ron) Martell
Mr. Ronald A. (Ron) Martell
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
33.12K
--
Mr. Jeetinder Singh (Jeet) Mahal
Mr. Jeetinder Singh (Jeet) Mahal
Chief Operating Officer
Chief Operating Officer
25.37K
+1.44%
Mr. Thomas G. (Tom) Wiggans
Mr. Thomas G. (Tom) Wiggans
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
4.73K
-5.40%
Mr. Vishal Kapoor
Mr. Vishal Kapoor
Independent Director
Independent Director
4.38K
--
Dr. Judith Shizuru, M.D., Ph.D.
Dr. Judith Shizuru, M.D., Ph.D.
Director
Director
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Kurt Von Emster
Mr. Kurt Von Emster
Independent Director
Independent Director
--
--
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
--
--
Mr. Christian W. Nolet
Mr. Christian W. Nolet
Independent Director
Independent Director
--
--
Mr. Herb Cross
Mr. Herb Cross
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Ronald A. (Ron) Martell
Mr. Ronald A. (Ron) Martell
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
33.12K
--
Mr. Jeetinder Singh (Jeet) Mahal
Mr. Jeetinder Singh (Jeet) Mahal
Chief Operating Officer
Chief Operating Officer
25.37K
+1.44%
Mr. Thomas G. (Tom) Wiggans
Mr. Thomas G. (Tom) Wiggans
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
4.73K
-5.40%
Mr. Vishal Kapoor
Mr. Vishal Kapoor
Independent Director
Independent Director
4.38K
--
Dr. Judith Shizuru, M.D., Ph.D.
Dr. Judith Shizuru, M.D., Ph.D.
Director
Director
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Mon, Jul 28
Updated: Mon, Jul 28
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Soleus Capital Management, L.P.
9.95%
Velan Capital Investment Management LP
9.54%
Abingworth Management Limited
7.10%
Qiming U.S. Ventures Management, LLC
6.18%
Kingdon Capital Management, L.L.C.
5.09%
Other
62.13%
Shareholders
Shareholders
Proportion
Soleus Capital Management, L.P.
9.95%
Velan Capital Investment Management LP
9.54%
Abingworth Management Limited
7.10%
Qiming U.S. Ventures Management, LLC
6.18%
Kingdon Capital Management, L.L.C.
5.09%
Other
62.13%
Shareholder Types
Shareholders
Proportion
Hedge Fund
27.36%
Investment Advisor
26.50%
Investment Advisor/Hedge Fund
20.26%
Research Firm
8.30%
Venture Capital
7.10%
Individual Investor
1.27%
Pension Fund
0.14%
Bank and Trust
0.07%
Other
9.00%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
200
13.39M
89.16%
-6.65M
2025Q1
208
13.43M
89.40%
-7.30M
2024Q4
197
16.02M
106.64%
-3.08M
2024Q3
183
15.58M
105.01%
-3.10M
2024Q2
159
15.59M
105.21%
-1.23M
2024Q1
125
13.80M
93.49%
+2.29M
2023Q4
104
8.47M
79.62%
-3.17M
2023Q3
105
10.07M
95.42%
-1.18M
2023Q2
146
9.80M
93.27%
-1.97M
2023Q1
144
10.30M
98.74%
+3.55M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Soleus Capital Management, L.P.
1.49M
9.95%
--
--
Mar 31, 2025
Velan Capital Investment Management LP
1.43M
9.54%
--
--
Mar 31, 2025
Abingworth Management Limited
1.07M
7.1%
--
--
Mar 31, 2025
Qiming U.S. Ventures Management, LLC
928.96K
6.18%
--
--
Mar 31, 2025
Kingdon Capital Management, L.L.C.
490.00K
3.26%
+43.00K
+9.62%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
731.63K
4.87%
-12.07K
-1.62%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
702.76K
4.68%
+620.59K
+755.30%
Mar 31, 2025
The Vanguard Group, Inc.
679.45K
4.52%
-30.03K
-4.23%
Mar 31, 2025
Morgan Stanley & Co. LLC
640.64K
4.26%
+212.56K
+49.65%
Mar 31, 2025
Integral Health Asset Management, LLC
575.00K
3.83%
-75.00K
-11.54%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.02%
Simplify Propel Opportunities ETF
0%
Vanguard US Momentum Factor ETF
0%
Tema Oncology ETF
0%
Proshares Ultra Russell 2000
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
Simplify Propel Opportunities ETF
Proportion0%
Vanguard US Momentum Factor ETF
Proportion0%
Tema Oncology ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 02, 2024
Merger
10<1
Jan 02, 2024
Merger
10<1
Jan 02, 2024
Merger
10<1
Jan 02, 2024
Merger
10<1
Date
Type
Ratio
Jan 02, 2024
Merger
10<1
Jan 02, 2024
Merger
10<1
Jan 02, 2024
Merger
10<1
Jan 02, 2024
Merger
10<1
